miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling
2018 · Oncogenesis · 90 citations
https://doi.org/10.1038/s41389-018-0097-8
R
Ruimin Chang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
77
Papers
2.8K
Citations
29
h-index
40
i10-index
Ruimin Chang is an academic researcher from Central South University. The author has contributed to research in topics: MicroRNA in disease regulation & Circular RNAs in diseases & RNA modifications and cancer. The author has an h-index of 29, co-authored 66 publications.
ORCID: 0000-0002-6067-6905Papers by this author
worksMicroRNA‐331‐3p inhibits epithelial‐mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/β‐catenin axis in non‐small‐cell lung cancer
2019 · Cancer Science · 66 citations
https://doi.org/10.1111/cas.14014
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
2024 · Journal of Cancer Research and Clinical Oncology · 8 citations
https://doi.org/10.1007/s00432-024-05703-8
Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12319571
Efficacy and safety of the optimal immunochemotherapy regimen for resectable non-small cell lung cancer: A network meta-analysis of randomized controlled trials
2025 · Asian Journal of Surgery · 0 citations
https://doi.org/10.1016/j.asjsur.2025.07.166
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat